AstraZeneca, Daiichi Sankyo in $6B oncology deal – MarketWatch

AstraZeneca PLC said Monday that it has entered into an oncology collaboration with Daiichi Sankyo Co. worth up to $6 billion that it said could redefine treatment standards in lung, breast and multiple other cancers.
The British pharmaceutical giant said it and Daiichi Sankyo will jointly develop and commercialize a new antibody drug conjugate, DS-1062, world-wide, except in Japan. The drug is currently in development, AstraZeneca said.
Under the collaboration, AstraZeneca will pay Daiichi Sa…

Click here to view the original article.